VERISILICON
4.3.2024 08:01:29 CET | Business Wire | Press release
VeriSilicon (688521.SH) today announced that HPMicro’s HPM6800 series, a new generation digital dashboard display and human-machine interface system application platform has adopted VeriSilicon’s high-performance 2.5D Graphics Processor Unit (GPU) IP.
HPM6800 series is based on RISC-V CPU cores, featuring robust computing power, low power consumption, high integration, and outstanding multimedia capabilities. It is the ideal solution for applications requiring complex graphics processing, high-resolution display and high-performance multimedia user interfaces, such as automotive dashboard, Human-Machine Interface (HMI), and Camera Monitor System (CMS).
VeriSilicon’s 2.5D GPU IP, which supports OpenVG, can provide MCU/MPU devices with high-efficiency graphics processing and high-quality image output while significantly reducing CPU load. With its proven scalability, it has been widely used in leading automotive, industrial, and wearable products. Additionally, VeriSilicon has collaborated with leading GUI software service providers to enrich the ecosystem for key GPU applications, effectively accelerating the market launch process for customer products.
“The HPM6800 series represents another innovation and breakthrough in our existing high-performance MCU product line,” said Jintao Zeng, CEO of HPMicro. “By integrating VeriSilicon’s advanced 2.5D GPU IP, HPM6800 not only inherits the strong computing power, precise control, and excellent communication performances of our existing MCU products, but also integrates efficient graphics processing, high-resolution display and other multimedia capabilities. We look forward to more industrial and automotive system solutions equipped with the HPM6800 high-performance MCUs.”
“This collaboration combines VeriSilicon’s rich-featured and low-power 2.5D GPU IP with HPMicro’s high-performance RISC-V based MCU, aiming to jointly launch leading products to address the growing market opportunities in the display field,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “Over the past decade, VeriSilicon’s 2.5D GPU IP has been widely used in many leading automotive and industrial products. We look forward to introducing this mature graphics processing technology into the RISC-V ecosystem to meet a wider range of customer needs.”
About HPMicro
HPMicro is a Chinese semiconductor company dedicated to offering high-performance MCUs and embedded solutions, with business involving microcontrollers, microprocessors, chipsets, as well as its supporting development tools and ecosystems. Founded in June 2020, the company’s headquartered in Shanghai, and has branches in Tianjin, Shenzhen, Suzhou and Hangzhou. At present, the company has completed ISO 9001 quality management certification and ISO 26262/IEC 61508 functional safety management system certification, fully serving the industrial, automotive and energy markets in China and the world. For more information, please visit our website https://hpmicro.com/
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240303801487/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom